Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash & Equivalents: 2023-2025

Historic Cash & Equivalents for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $45.1 million.

  • CG Oncology's Cash & Equivalents rose 3.99% to $45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.1 million, marking a year-over-year increase of 3.99%. This contributed to the annual value of $257.1 million for FY2024, which is 3009.94% up from last year.
  • CG Oncology's Cash & Equivalents amounted to $45.1 million in Q3 2025, which was up 208.70% from $14.6 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Cash & Equivalents registered a high of $257.1 million during Q4 2024, and its lowest value of $8.3 million during Q4 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $42.4 million (2024), whereas its average is $64.1 million.
  • Per our database at Business Quant, CG Oncology's Cash & Equivalents soared by 3,009.94% in 2024 and then tumbled by 46.47% in 2025.
  • CG Oncology's Cash & Equivalents (Quarterly) stood at $8.3 million in 2023, then skyrocketed by 3,009.94% to $257.1 million in 2024, then rose by 3.99% to $45.1 million in 2025.
  • Its Cash & Equivalents stands at $45.1 million for Q3 2025, versus $14.6 million for Q2 2025 and $41.5 million for Q1 2025.